Longbio Pharma (Suzhou) Co (HKSE:01779) Total Inventories: HK$0.00 Mil (As of Dec. 2025)


HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$157.20
View Full Analysis

What is Longbio Pharma (Suzhou) Co Total Inventories?

Longbio Pharma (Suzhou) Co HKSE:01779 +3.63% 10 Total Inventories is HK$0.00 Mil as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

Longbio Pharma (Suzhou) Co's total inventories for the quarter that ended in Dec. 2025 was HK$0.00 Mil. Longbio Pharma (Suzhou) Co's average total inventories from the quarter that ended in Dec. 2024 to the quarter that ended in Dec. 2025 was HK$0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Longbio Pharma (Suzhou) Co's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$1.55.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Longbio Pharma (Suzhou) Co  (HKSE:01779) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Longbio Pharma (Suzhou) Co's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(211.16+0.75 * 0+0.5 * 0-96.157
-0-0)/74.193
=1.55

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Longbio Pharma (Suzhou) Co's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=0/0*365 / 2
=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Longbio Pharma (Suzhou) Co's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=0 / 0
=N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Longbio Pharma (Suzhou) Co's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Longbio Pharma (Suzhou) Co Total Inventories Related Terms

Longbio Pharma (Suzhou) Co Total Inventories Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co Total Inventories Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
Total Inventories
0.00 0.00

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
Total Inventories 0.00 0.00
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of HK$0.00 Mil mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Total Inventories of HK$0.00 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Longbio Pharma (Suzhou) Co and its competitors.
Is Longbio Pharma (Suzhou) Co's Total Inventories too high?
Longbio Pharma (Suzhou) Co's current Total Inventories is HK$0.00 Mil. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Total Inventories compare to ?
Longbio Pharma (Suzhou) Co's Total Inventories of HK$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current Total Inventories is HK$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Total Inventories of HK$0.00 Mil. The current Total Inventories is HK$0.00 Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Total Inventories is HK$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Comparable Companies
Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$157.20
Price